Acute respiratory tract infections are significant causes of morbidity and mortality worldwide.1-5 Many acute respiratory illnesses present with similar symptoms, with different types of treatment available for some illnesses. Therefore, quick and accurate identification of the viral pathogen causing the symptoms can lead to proper treatment within an effective time frame and help prevent further transmission.
Roche is excited to share that the cobas® Respiratory flex assay is now included on the Australian Register of Therapeutics Goods, and is available in Australia.
cobas Respiratory flex for use on the cobas 5800/6800/8800 systems is an automated, multiplex, nucleic acid test that utilises real-time polymerase chain reaction (PCR) technology for simultaneous in vitro qualitative detection and differentiation of 12 viral targets from one well: